Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside.
Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer’s that targets extracellular and intracellular tau
The company had previously submitted an Investigational New Drug (IND) application, and this recent clearance will allow Voyager to begin VY1706 clinical trials on individuals with preliminary symptoms of Alzheimer’s. Dosages are projected to start during the last 6 months of 2026. Pressmaster/ The company CEO, Alfred W.
Sandrock, reflected favorably on this development that followed a thorough preclinical process. He emphasized how reducing tau can be a crucial step in curing Alzheimer’s. Sandrock stated: “The IND clearance for VY1706 is the first for a tau-targeted gene therapy and follows a comprehensive preclinical program demonstrating a compelling pharmacology and safety profile.